Recombinant Human Erythropoietin: Factors to Consider in Cost-Benefit Analysis
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- January 1991
has subject area
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- Anemia (MeSH)
- Blood Transfusion (MeSH)
- Cost-Benefit Analysis (MeSH)
- Erythropoietin (MeSH)
- Humans (MeSH)
- Insurance, Health, Reimbursement (MeSH)
- Kidney Failure, Chronic (MeSH)
- Quality of Life (MeSH)
- Recombinant Proteins (MeSH)
- Renal Dialysis (MeSH)
- Socioeconomic Factors (MeSH)
- Urology & Nephrology (Science Metrix)